The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: A longitudinal data analysis
Abstract
Purpose To determine the effect of prednisone dose and hydroxychloroquine dose on the coronary artery disease risk factors serum cholesterol level, mean arterial blood pressure, and weight in patients with systemic lupus erythematosus.Patients and methods A longitudinal cohort study of 264 patients with systemic lupus erythematosus was conducted. For all patients in the cohort, serum cholesterol, mean arterial pressure, weight, prednisone dose, hydroxychloroquine dose, and other potential confounding variables were recorded at each visit. Regression analysis appropriate for longitudinal data was used to assess the effect of prednisone on serum cholesterol and mean arterial pressure. To assess the effect of prednisone on weight, patients' weights were compared 90 days before and after a 10-mg or 20-mg increase in prednisone.Results A total of 3,027 patient visits were analyzed. In the regression model for serum cholesterol, a change in prednisone dose of 10 mg was associated with a change in cholesterol of 7.5 +/- 1.46 (SE) mg% after adjustment for the other significant variables in the model, including sex, race, hydroxychloroquine dose, and proteinuria. In the regression model for hydroxychloroquine, the 200-mg and the 400-mg dose were both associated with lower serum cholesterol (8.9 +/- 3.44 SE mg%). In the regression model for mean arterial blood pressure, a 10-mg change in prednisone dose led to a change in mean arterial blood pressure of 1.1 mm Hg after adjustment for age, weight, and antihypertensive drug use. A 10-mg increase in prednisone dose was associated with a mean weight change of 5.50 +/- 1.23 (SE) lb.Conclusions Changes in prednisone dose led to definable changes in risk factors for coronary artery disease, even after adjustment for other variables known to affect these risk factors. According to longitudinal regression analysis, hydroxychloroquine therapy was associated with lower serum cholesterol.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Multiple retrospective and a few prospective studies (3–13) have found that hydroxychloroquine (HCQ) reduces the risk of arterial and venous thrombosis.”
From Association of Higher Hydroxychloroquine Blood Levels With Reduced Thrombosis Risk in Systemic Lupus Erythematosus (2021) · cites this paper as [5]
Citations
Cites
Longitudinal data analysis using generalized linear models
LIANG, K.-Y., & ZEGER, S. L. (1986) · Biometrika · doi:10.1093/biomet/73.1.13 · Cited by 18,550
Longitudinal Data Analysis for Discrete and Continuous Outcomes
Zeger, S. L., & Liang, K. (1986) · Biometrics · doi:10.2307/2531248 · Cited by 7,781
The Lipid Research Clinics Coronary Primary Prevention Trial Results
(1984) · JAMA · doi:10.1001/jama.1984.03340270043026 · Cited by 1,404
The bimodal mortality pattern of systemic lupus erythematosus
Urowitz, M. B., BOOKMAN, A. A. M., Koehler, B. E., Gordon, D. A., SMYTHE, H. A., & Ogryzlo, M. A. (1976) · The American Journal of Medicine · doi:10.1016/0002-9343(76)90431-9 · Cited by 999
Lipid Research Clinics Program
Renfrew, R. A. (1984) · JAMA · doi:10.1001/jama.1984.03350180015009 · Cited by 829
The Effects of Nonpharmacologic Interventions on Blood Pressure of Persons With High Normal Levels
Whelton, P. K. (1992) · JAMA · doi:10.1001/jama.1992.03480090061028 · Cited by 768
The Canadian Hydroxychloroquine Study Group* (1991) · New England Journal of Medicine · doi:10.1056/nejm199101173240303 · Cited by 676
The heart in systemic lupus erythematosus and the changes induced in it by corticosteroid therapy
Bulkley, B. H., & Roberts, W. C. (1975) · The American Journal of Medicine · doi:10.1016/0002-9343(75)90575-6 · Cited by 672
Risk factors for coronary artery disease in patients with systemic lupus erythematosus
Petri, M., Perez‐Gutthann, S., Spence, D., & Hochberg, M. C. (1992) · The American Journal of Medicine · doi:10.1016/0002-9343(92)90578-y · Cited by 623
Self-citation
Research works printed but not linked: 2
- Cumming, 1989, Cardiovascular disease-related knowledge and attitudes in a high-risk Australian population, Med J Aust, 150, 556, 10.5694/j.1326-5377.1989.tb136692.x · DOI
- Bush, 1988, Cholesterol, lipoproteins, and coronary heart disease in woman, Clin Chem, 34, B60
Cited by
Sorted by citations
Prevalence and Correlates of Accelerated Atherosclerosis in Systemic Lupus Erythematosus
Roman, M. J., Shanker, B., Davis, A., Lockshin, M. D., Sammaritano, L. R., Simantov, R., Crow, M. K., Schwartz, J. E., Paget, S. A., Devereux, R. B., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035471 · Cited by 1,422
Ruiz-Irastorza, G., Ramos-Casals, M., Brito-Zeron, P., & Khamashta, M. A. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.101766 · Cited by 978
Systemic lupus erythematosus: Diagnosis and clinical management
Fava, A., & Petri, M. (2018) · Journal of Autoimmunity · doi:10.1016/j.jaut.2018.11.001 · Cited by 818
Self-citationAccelerated atherosclerosis: An extraarticular feature of rheumatoid arthritis?
Doornum, S. V., McColl, G., & Wicks, I. P. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10089 · Cited by 606
Economic consequences of the progression of rheumatoid arthritis in Sweden
Kobelt, G., Eberhardt, K., J�nsson, L., & J�nsson, B. (1999) · Arthritis & Rheumatism · doi:10.1002/1529-0131(199902)42:2 · Cited by 167
Rovere, P. Q., Sabbadini, M. G., Fazzini, F., Bondanza, A., Zimmermann, V. S., Rugarli, C., & Manfredi, A. A. (2000) · Arthritis & Rheumatism · doi:10.1002/1529-0131(200008)43:8 · Cited by 85
Self-citationEffect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus
Ruiz-Irastorza, G., Egurbide, M.-V., Pijoan, J.-I., Garmendia, M., Villar, I., Martinez-Berriotxoa, A., Erdozain, J.-G., & Aguirre, C. (2006) · Lupus · doi:10.1177/0961203306071872 · Cited by 411
Cardiac involvement in systemic lupus erythematosus
Doria, A., Iaccarino, L., Sarzi‐Puttini, P., Atzeni, F., Turiel, M., & Petri, M. (2005) · Lupus · doi:10.1191/0961203305lu2200oa · Cited by 396
Self-citationBruce, I. N., Urowitz, M. B., Gladman, D. D., Ibañez, D., & Steiner, G. A. (2003) · Arthritis & Rheumatism · doi:10.1002/art.11296 · Cited by 395
Fessler, B. J., Alarcón, G. S., McGwin, G., Roseman, J. M., Bastian, H. M., Friedman, A., Baethge, B. A., Vilá, L. M., Reveille, J. D., & for the LUMINA Study Group (2005) · Arthritis & Rheumatism · doi:10.1002/art.21039 · Cited by 377
Mosca, M., Tani, C., Aringer, M., Bombardieri, S., Boumpas, D., Brey, R. L., Cervera, R., Doria, A., Jayne, D. R. W., Khamashta, M. A., et al. (2009) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2009.117200 · Cited by 382
Self-citationSchoenfeld, S. R., Kasturi, S., & Costenbader, K. H. (2013) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2012.12.002 · Cited by 370
Prevalence and burden of pediatric-onset systemic lupus erythematosus
Kamphuis, S. S. M., & Silverman, E. D. (2010) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2010.121 · Cited by 359
Toloza, S., Uribe, A. G., McGwin, G., Alarcón, G. S., Fessler, B. J., Bastian, H. M., Vilá, L. M., Wu, R., Shoenfeld, Y., Roseman, J. M., et al. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20622 · Cited by 319
Hypertension in rheumatoid arthritis
Panoulas, V. F., Metsios, G. S., Pace, A. V., John, H., Treharne, G. J., Banks, M., & Kitas, G. D. (2008) · Rheumatology · doi:10.1093/rheumatology/ken159 · Cited by 309
Cardiac Involvement in Systemic Lupus Erythematosus
Moder, K. G., Miller, T. D., & Tazelaar, H. D. (1999) · Mayo Clinic Proceedings · doi:10.4065/74.3.275 · Cited by 292
Borba, E. F., & Bonfá, E. (1997) · Lupus · doi:10.1177/096120339700600610 · Cited by 289
Magder, L. S., & Petri, M. (2012) · American Journal of Epidemiology · doi:10.1093/aje/kws130 · Cited by 290
Self-citationBruce, I. N. (2005) · Rheumatology · doi:10.1093/rheumatology/kei142 · Cited by 276
Guidelines for referral and management of systemic lupus erythematosus in adults
Wolfe, F., & Pincus, T. (1999) · Arthritis & Rheumatism · doi:10.1002/1529-0131(199909)42:9 · Cited by 269
Hydroxychloroquine use in the Baltimore Lupus Cohort: effects on lipids, glucose and thrombosis
Petri, M. (1996) · Lupus · doi:10.1177/0961203396005001051 · Cited by 259
Self-citationGlucocorticoid use and abuse in SLE
Ruiz‐Irastorza, G., Danza, Ã., & Khamashta, M. A. (2012) · Rheumatology · doi:10.1093/rheumatology/ker410 · Cited by 254
PREMATURE ATHEROSCLEROSIS IN SYSTEMIC LUPUS ERYTHEMATOSUS
Bruce, I. N., Gladman, D. D., & Urowitz, M. B. (2000) · Rheumatic Disease Clinics of North America · doi:10.1016/s0889-857x(05)70138-1 · Cited by 240
The role of antimalarial agents in the treatment of SLE and lupus nephritis
Lee, S., Silverman, E. D., & Bargman, J. M. (2011) · Nature Reviews Nephrology · doi:10.1038/nrneph.2011.150 · Cited by 241
Innala, L., Möller, B., Ljung, L., Magnusson, S., Smedby, T., Södergren, A., Öhman, M., Rantapää‐Dahlqvist, S., & Wållberg‐Jonsson, S. (2011) · Arthritis Research & Therapy · doi:10.1186/ar3442 · Cited by 230
Petri, M. (2000) · Lupus · doi:10.1191/096120300678828226 · Cited by 219
Self-citationNew insights into mechanisms of therapeutic effects of antimalarial agents in SLE
Wallace, D. J., Gudsoorkar, V. S., Weisman, M. H., & Venuturupalli, S. R. (2012) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2012.106 · Cited by 221
Hydroxychloroquine in systemic lupus erythematosus: overview of current knowledge
Dima, A., Jurcuț, C., Chasset, F., Felten, R., & Arnaud, L. (2022) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x211073001 · Cited by 239
Surviving the butterfly and the wolf: mortality trends in systemic lupus erythematosus
Borchers, A. T., Keen, C. L., Shoenfeld, Y., & Gershwin, M. E. (2004) · Autoimmunity Reviews · doi:10.1016/j.autrev.2004.04.002 · Cited by 206
Cardiac Manifestations of Systemic Lupus Erythematosus
Miner, J. J., & Kim, A. H. J. (2013) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2013.10.003 · Cited by 203
Hydroxychloroquine: A multifaceted treatment in lupus
Costedoat-Chalumeau, N., Dunogué, B., Morel, N., Guern, V. L., & Guettrot-Imbert, G. (2014) · La Presse Médicale · doi:10.1016/j.lpm.2014.03.007 · Cited by 195
Tackling ischaemic heart disease in rheumatoid arthritis
Kitas, G. D. (2003) · British journal of rheumatology · doi:10.1093/rheumatology/keg175 · Cited by 180
Thrombosis and Systemic Lupus Erythematosus: The Hopkins Lupus Cohort Perspective
Petri, M. (1996) · Scandinavian Journal of Rheumatology · doi:10.3109/03009749609069986 · Cited by 176
Self-citationCardiovascular disease in systemic lupus erythematosus: A comprehensive update
Giannelou, M., & Mavragani, C. P. (2017) · Journal of Autoimmunity · doi:10.1016/j.jaut.2017.05.008 · Cited by 172
Gerstein, H. C., Thorpe, K. E., Taylor, D. W., & Haynes, R. B. (2002) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(01)00325-4 · Cited by 169
Quirós-Roldán, E., Biasiotto, G., Magro, P., & Zanella, I. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104904 · Cited by 153
Akhavan, P. S., Su, J., Lou, W. Y. W., Gladman, D. D., Urowitz, M. B., & Fortin, P. R. (2013) · The Journal of Rheumatology · doi:10.3899/jrheum.120572 · Cited by 147
Schanberg, L. E., Sandborg, C. I., Barnhart, H. X., Ardoin, S. P., Yow, E. S., Evans, G. W., Mieszkalski, K. L., Ilowite, N. T., Eberhard, A., Levy, D. M., et al. (2009) · Arthritis & Rheumatism · doi:10.1002/art.24469 · Cited by 145
Morris, S. J., Wasko, M. C., Antohe, J. L., Sartorius, J. A., Kirchner, H. L., Dancea, S., & Bili, A. (2010) · Arthritis Care & Research · doi:10.1002/acr.20393 · Cited by 144
Multifaceted effects of hydroxychloroquine in human disease
Olsen, N. J., Schleich, M. A., & Karp, D. R. (2013) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2013.01.001 · Cited by 147
Cairoli, E., Rebella, M., Danese, N., Garra, V., & Borba, E. F. (2012) · Lupus · doi:10.1177/0961203312450084 · Cited by 138
Determinants of Hydroxychloroquine Blood Concentration Variations in Systemic Lupus Erythematosus
Jallouli, M., Galicier, L., Zahr, N., Aumaître, O., Francès, C., Guern, V. L., Lioté, F., Смаил, А., Limal, N., Pérard, L., et al. (2015) · Arthritis & Rheumatology · doi:10.1002/art.39194 · Cited by 136
Nord, J. E., Shah, P. K., Rinaldi, R. Z., & Weisman, M. H. (2004) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2003.09.012 · Cited by 137
Dyslipidemia in systemic lupus erythematosus
Szabó, M. Z., Szodoray, P., & Kiss, E. V. (2017) · Immunologic Research · doi:10.1007/s12026-016-8892-9 · Cited by 138
Effect of disease modifying agents on the lipid profiles of patients with rheumatoid arthritis
Munro, R., Morrison, E., McDonald, A. G., Hunter, J. A., Madhok, R., & Capell, H. A. (1997) · Annals of the Rheumatic Diseases · doi:10.1136/ard.56.6.374 · Cited by 134
Accelerated Atherosclerosis in Rheumatoid Arthritis
Szekanecz, Z., Kerekes, G., Dér, H., Sándor, Z., Szabó, Z., VÉGVÁRI, A., SIMKOVICS, E., Soós, L., Szentpétery, Á., Besenyei, T., et al. (2007) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1422.036 · Cited by 129
Nuri, E., Taraborelli, M., Andreoli, L., Tonello, M., Gerosa, M., Calligaro, A., Argolini, L. M., Kumar, R., Pengo, V., Meroni, P. L., et al. (2017) · Immunologic Research · doi:10.1007/s12026-016-8812-z · Cited by 123
Premature atherosclerotic cardiovascular disease in systemic lupus erythematosus
Westerweel, P. E., Luyten, R. K. M. A. C., Koomans, H. A., Derksen, R. H. W. M., & Verhaar, M. C. (2007) · Arthritis & Rheumatism · doi:10.1002/art.22568 · Cited by 124
Petri, M. (2000) · Rheumatic Disease Clinics of North America · doi:10.1016/s0889-857x(05)70135-6 · Cited by 120
Self-citationPons‐Estel, G., Gonzalez, L. A., Zhang, J., Burgos, P. I., Reveille, J. D., Vilá, L. M., & Alarcón, G. S. (2009) · Rheumatology · doi:10.1093/rheumatology/kep102 · Cited by 122
Hydroxychloroquine as an anti-thrombotic in antiphospholipid syndrome
Belizna, C. (2015) · Autoimmunity Reviews · doi:10.1016/j.autrev.2014.12.006 · Cited by 118
Liu, D., Li, X., Zhang, Y., Kwong, J. S. W., Li, L., Zhang, Y., Xu, C., Li, Q., Sun, X., Tian, H., et al. (2018) · Drug Design Development and Therapy · doi:10.2147/dddt.s166893 · Cited by 116
Sabio, J. M., Vargas‐Hitos, J. A., Navarrete‐Navarrete, N., Mediavilla, J. D., Jiménez‐Jáimez, J., Díaz‐Chamorro, A., & Jiménez-Alonso, J. F. (2011) · The Journal of Rheumatology · doi:10.3899/jrheum.101132 · Cited by 116
Westerweel, P. E., Luijten, R. K. M. A. C., Hoefer, I. E., Koomans, H. A., Derksen, R. H. W. M., & Verhaar, M. C. (2007) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2006.065631 · Cited by 113
PATHOGENESIS AND TREATMENT OF THE ANTIPHOSPHOLIPID ANTIBODY SYNDROME
Petri, M. (1997) · Medical Clinics of North America · doi:10.1016/s0025-7125(05)70509-5 · Cited by 112
Self-citationWard, M. M. (2004) · Journal of Women s Health · doi:10.1089/jwh.2004.13.713 · Cited by 110
Karp, I., Abrahamowicz, M., Fortin, P. R., Pilote, L., Neville, C., Pineau, C. A., & Esdaile, J. M. (2008) · Arthritis Care & Research · doi:10.1002/art.23352 · Cited by 109
Hage, M. P., Al-Badri, M. R., & Azar, S. T. (2014) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018814547204 · Cited by 98
Metabolic syndrome in patients with systemic lupus erythematosus from Southern Spain
Sabio, J. M., Zamora‐Pasadas, M., Jiménez‐Jáimez, J., Albadalejo, F., Vargas‐Hitos, J. A., del Águila, M. M. R., Hidalgo-Tenorio, C., González-Gay, M. Á., & Alonso, J. (2008) · Lupus · doi:10.1177/0961203308093554 · Cited by 97
Treatment of severe lupus nephritis: the new horizon
Chan, T. M. (2014) · Nature Reviews Nephrology · doi:10.1038/nrneph.2014.215 · Cited by 94
Hydroxychloroquine in lupus: emerging evidence supporting multiple beneficial effects
Tang, C., Godfrey, T., Stawell, R. J., & Nikpour, M. (2012) · Internal Medicine Journal · doi:10.1111/j.1445-5994.2012.02886.x · Cited by 94
Nuttall, S. L. (2003) · British journal of rheumatology · doi:10.1093/rheumatology/keg212 · Cited by 90
Nikpour, M., Urowitz, M. B., Ibañez, D., Harvey, P., & Gladman, D. D. (2011) · Arthritis Research & Therapy · doi:10.1186/ar3473 · Cited by 86
Neto, E. T. D. R., Kakehasi, A. M., Pinheiro, M. A. A., Ferreira, G. A., Marques, C. D. L., da Mota, L. M. H., Paiva, E. D. S., Pileggi, G. S., Sato, E. I., Gomides, A. P. M., et al. (2020) · Revista Brasileira de Reumatologia · doi:10.1186/s42358-020-00134-8 · Cited by 88
Floris, A., Piga, M., Mangoni, A. A., Bortoluzzi, A., Erre, G. L., & Cauli, A. (2018) · Mediators of Inflammation · doi:10.1155/2018/3424136 · Cited by 84
Comparison of alternative models for linking drug exposure with adverse effects
Abrahamowicz, M., Beauchamp, M., & Sylvestre, M. (2011) · Statistics in Medicine · doi:10.1002/sim.4343 · Cited by 82
Mechanisms of Dyslipoproteinemias in Systemic Lupus Erythematosus
Borba, E. F., de Carvalho, J. F., & Bonfá, E. (2006) · Journal of Immunology Research · doi:10.1080/17402520600876945 · Cited by 81
Feldt, J. M. V. (1995) · Postgraduate Medicine · doi:10.1080/00325481.1995.11945982 · Cited by 81
Coronary artery disease in systemic lupus erythematosus: A review of the literature
Karrar, A., Sequeira, W., & Block, J. A. (2001) · Seminars in Arthritis and Rheumatism · doi:10.1053/sarh.2001.23498 · Cited by 79
Rho, Y. H., Oeser, A. M., Chung, C. P., Milne, G. L., & Stein, C. M. (2009) · Archives of Drug Information · doi:10.1111/j.1753-5174.2009.00019.x · Cited by 78
Current and emerging treatment options in the management of lupus
Jordan, N., & D’Cruz, D. P. (2016) · ImmunoTargets and Therapy · doi:10.2147/itt.s40675 · Cited by 78
Libourel, E. J., Sonneveld, P., van der Holt, B., de Maat, M. P. M., & Leebeek, F. W. G. (2010) · Blood · doi:10.1182/blood-2009-12-257519 · Cited by 77
Contemporary treatment of systemic lupus erythematosus: an update for clinicians
Amissah-Arthur, M., & Gordon, C. (2010) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622310380100 · Cited by 76
Mok, C. C., Tse, S. M., Chan, K. L., & Ho, L. Y. (2017) · Lupus · doi:10.1177/0961203317739129 · Cited by 76
Hydroxychloroquine: the cornerstone of lupus therapy
Ruiz‐Irastorza, G., & Khamashta, M. A. (2008) · Lupus · doi:10.1177/0961203307086643 · Cited by 76
Virdis, A., Tani, C., Duranti, E., Vagnani, S., Carli, L., Kühl, A. A., Solini, A., Baldini, C., Talarico, R., Bombardieri, S., et al. (2015) · Arthritis Research & Therapy · doi:10.1186/s13075-015-0790-3 · Cited by 72
Antimalarials—the ‘real‘ advance in lupus
Wallace, D. J. (2001) · Lupus · doi:10.1191/096120301678646092 · Cited by 72
Arterial Events in Persons with Dermatomyositis and Polymyositis
Tisseverasinghe, A., Bernatsky, S., & Pineau, C. A. (2009) · The Journal of Rheumatology · doi:10.3899/jrheum.090061 · Cited by 72
Disease modification and cardiovascular risk reduction: two sides of the same coin?
Hall, F. C., & Dalbeth, N. (2005) · Rheumatology · doi:10.1093/rheumatology/kei012 · Cited by 71
Early atherosclerosis in systemic sclerosis and its relation to disease or traditional risk factors
Hettema, M. E., Zhang, D., de Leeuw, K., Stienstra, Y., Smit, A. J., Kallenberg, C. G. M., & Bootsma, H. (2008) · Arthritis Research & Therapy · doi:10.1186/ar2408 · Cited by 71
Antimalarials in cutaneous lupus erythematosus: mechanisms of therapeutic benefit
Woźniacka, A. J., Carter, A., & McCauliffe, D. P. (2002) · Lupus · doi:10.1191/0961203302lu147rr · Cited by 69
Solomon, D. H., Garg, R., Lü, B., Todd, D. J., Mercer, E., Norton, T., & Massarotti, E. M. (2014) · Arthritis Care & Research · doi:10.1002/acr.22285 · Cited by 68
How to improve morbidity and mortality in systemic lupus erythematosus
Urowitz, M. B. (2000) · British journal of rheumatology · doi:10.1093/rheumatology/39.3.238 · Cited by 67
Cardiovascular risk in pediatric-onset rheumatological diseases
Barsalou, J., Bradley, T. J., & Silverman, E. D. (2013) · Arthritis Research & Therapy · doi:10.1186/ar4212 · Cited by 67
Petri, M., Konig, M. F., Li, J., & Goldman, D. W. (2021) · Arthritis & Rheumatology · doi:10.1002/art.41621 · Cited by 70
“comorbidity factors including diabetes (20) and hyperlipidemia (5).”
BackgroundSelf-citationDevelopment of a systemic lupus erythematosus cardiovascular risk equation
Petri, M., Barr, E. A., & Magder, L. S. (2019) · Lupus Science & Medicine · doi:10.1136/lupus-2019-000346 · Cited by 65
Self-citationChloroquine increases low-density lipoprotein removal from plasma in systemic lupus patients
Sachet, J. C., Borba, E. F., Bonfá, E., Vinagre, C. G. C., Silva, V. M., & Maranhão, R. C. (2007) · Lupus · doi:10.1177/09612033070160040901 · Cited by 64
Cardiovascular disease in lupus patients: Should all patients be treated with statins and aspirin?
Bruce, I. N. (2005) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2005.05.001 · Cited by 61
Lee, A. B., Godfrey, T., Rowley, K., Karschimkus, C. S., Dragicevic, G., Romas, E., Clemens, L., Wilson, A. M., Nikpour, M., Prior, D., et al. (2006) · Internal Medicine Journal · doi:10.1111/j.1445-5994.2006.01044.x · Cited by 60
Frerix, M., Stegbauer, J., Kreuter, A., & Weiner, S. M. (2014) · Arthritis Research & Therapy · doi:10.1186/ar4489 · Cited by 60
Atherosclerosis in systemic lupus erythematosus
Croca, S. C., & Rahman, A. (2017) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2017.09.012 · Cited by 60
Definitions of and contributions to cardiovascular disease in systemic lupus erythematosus
Gustafsson, J. T., & Svenungsson, E. (2013) · Autoimmunity · doi:10.3109/08916934.2013.856005 · Cited by 59
Microcirculatory Hemodynamics and Endothelial Dysfunction in Systemic Lupus Erythematosus
Wright, S., O’Prey, F. M., Rea, D. J., Plumb, R., Gamble, A., Leahey, W. J., Devine, A. B., McGivern, R. C., Johnston, D., Finch, M. B., et al. (2006) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000238351.82900.7f · Cited by 58
Hernández‐Cruz, B., Tapia, N., Villa-Romero, A. R., Reyes, E., & Cardiel, M. H. (2001) · PubMed · Cited by 57
Consenso de lúpus eritematoso sistêmico
Borba, E. F., Latorre, L. C., Brenol, J. C. T., Kayser, C., da Silva, N. A., Zimmermann, A. F., de Pádua, P. M., Costallat, L. T. L., Bonfá, E., & Sato, E. I. (2008) · Revista Brasileira de Reumatologia · doi:10.1590/s0482-50042008000400002 · Cited by 56
Omdal, P. L. R. (2001) · Scandinavian Journal of Rheumatology · doi:10.1080/030097401753180354 · Cited by 56
Babary, H., Liu, X., Ayatollahi, Y., Chen, X. P., Doo, L. D., Uppaluru, L. K., Kwak, M. K., Kulaga, C., Modjinou, D. V., Olech, E., et al. (2017) · International Journal of Rheumatic Diseases · doi:10.1111/1756-185x.13159 · Cited by 56
Accelerated atheroma in lupus—background
Urowitz, M. B., & Gladman, D. D. (2000) · Lupus · doi:10.1191/096120300678828271 · Cited by 56
Cardiovascular Implications of Immune Disorders in Women
Moran, C. A., Collins, L. F., Beydoun, N., Mehta, P. K., Fatade, Y., Isiadinso, I., Lewis, T. T., Weber, B., Goldstein, J. M., Ofotokun, I., et al. (2022) · Circulation Research · doi:10.1161/circresaha.121.319877 · Cited by 57
Chaiamnuay, S., Bertoli, A. M., Roseman, J. M., McGwin, G., Apte, M., Duran, S., Vilá, L. M., Reveille, J. D., & Alarcón, G. S. (2006) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2006.059311 · Cited by 54
Metadata
- Authors
- Petri, M., Lakatta, C., Magder, L., & Goldman, D.
- Affiliations
- Johns Hopkins University (US)
- Corresponding author
- Petri, Michelle
- Venue
- The American Journal of Medicine
- Publisher
- Elsevier BV
- Published
- 1994-03
- Volume
- 96
- Issue
- 3
- Pages
- 254-259
- ISSN
- 0002-9343 (ISSN-L)
- OpenAlex
- W2021741488
- Cited by
- 323
- References
- 25
- Citations by year
- 2026: 5 · 2025: 2 · 2024: 4 · 2023: 5 · 2022: 10 · 2021: 12 · 2020: 8 · 2019: 6 · 2018: 10 · 2017: 14 · 2016: 6 · 2015: 6 · 2014: 16 · 2013: 15 · 2012: 23
- FWCI
- 2.88
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The American Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5r29hl047080-02)
- National Heart, Lung, and Blood Institute (HL 47080-01)
- Topics
- Health Sciences › Medicine › Rheumatology › Systemic Lupus Erythematosus Research
- Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Keywords
- systemic lupus erythematosus, prednisone, hydroxychloroquine, coronary risk factors, serum cholesterol, mean arterial pressure, body weight, glucocorticoid dose, hypolipidemic effect
- MeSH terms
- Adult, Blood Pressure, Body Weight, Cholesterol, Coronary Disease, Female, Humans, Hydroxychloroquine, Lupus Erythematosus, Systemic, Male, Middle Aged, Prednisone, Regression Analysis, Risk Factors, Linear Models
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review